Aardvark Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-21$15.82 RISE2026-03-26$3.51 PEAK2026-05-14$6.73 113d | -77.8% 64d | Missed | Missed | — | — | +91.7% 49d | Missed |
DROP2025-10-07$17.41 RISE2025-12-02$9.26 PEAK2026-01-21$15.82 106d | -46.8% 56d | Missed | Missed | — | — | +70.8% 50d | Missed |
DROP2025-06-24$15.76 RISE2025-09-11$7.79 PEAK2025-10-07$17.41 105d | -50.6% 79d | Missed | Missed | — | — | +123.5% 26d | Missed |
DROP2025-02-20$17.25 RISE2025-04-17$7.00 PEAK2025-06-24$15.76 124d | -59.4% 56d | Missed | Missed | — | — | +125.1% 68d | Missed |
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Aardvark Therapeutics, Inc. stock: FDA clinical hold on ARD-101, cash-backed valuation, and key catalysts ahead. Click for more on recent developments with AARD.
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
LanzaTech Global (LNZA) signed a securities purchase agreement with certain institutional investors
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.
B. Riley Securities analyst William Woods maintains Aardvark Therapeutics (NASDAQ:AARD) with a Buy and lowers the price target from $8 to $7.
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.
By Christopher Kuo Aardvark Therapeutics shares plunged after the Food and Drug Administration placed a full clinical hold on the company's investigational new-drug application for ARD-101,...
BTIG analyst Jeet Mukherjee downgrades Aardvark Therapeutics (NASDAQ:AARD) from Buy to Neutral.
FDA places full clinical hold on Aardvark's ARD-101 studies as the company reviews Phase 3 safety and efficacy data.
Top Wall Street analysts upgraded RXO, BWXT, and Timken stocks with higher price targets. See other analysts' views on these stocks.
Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.
Morgan Stanley analyst Michael Ulz downgrades Aardvark Therapeutics (NASDAQ:AARD) from Equal-Weight to Underweight and lowers the price target from $7 to $3.
Figma Inc (NYSE: FIG) shares rose 10.6% in pre-market trading after beating Q1 revenue and earnings estimates and raising FY26 sales guidance.
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AARD | -24.73% | -24.86% | -68.69% | -60.63% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -27.69% | -19.15% | -65.24% | -73.32% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 199.3K | $751.44K | 0.00% | Added+26.0% | 2026-03-31 |
| TwoSigma | quant | 163.4K | $615.85K | 0.00% | Added+26.8% | 2026-03-31 |
| RenTech | quant | 70.8K | $266.89K | 0.00% | New | 2026-03-31 |
| FidelityFMR | fundamental | 9.0K | $33.77K | 0.00% | Added+613.2% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-11 | Lee Tien-Li | Chief Executive Officer | A Grant / award(deriv) | 203,851 | — | +$0 |
| 2026-02-11 | Jaiman Manasi | Chief Medical Officer | A Grant / award(deriv) | 70,549 | — | +$0 |
| 2026-02-11 | Sun Nelson | Chief Financial Officer | A Grant / award(deriv) | 70,549 | — | +$0 |
| 2025-12-12 | Lee Tien-Li | Chief Executive Officer | P Open-market purchase | 7,000 | $14.48 | +$101.4K |
| 2025-12-12 | Sun Nelson | Chief Financial Officer | P Open-market purchase | 3,000 | $14.40 | +$43.2K |
| 2025-10-16 | Jones Bryan | Chief Operating Officer | M Option exercise(deriv) | 1,250 | — | +$0 |
| 2025-10-16 | Jones Bryan | Chief Operating Officer | M Option exercise | 1,250 | $4.24 | +$5.3K |
| 2025-10-16 | Lee Tien-Li | Chief Executive Officer | M Option exercise(deriv) | 1,229 | — | +$0 |
| 2025-10-16 | Lee Tien-Li | Chief Executive Officer | M Option exercise | 1,229 | $4.24 | +$5.2K |
| 2025-09-16 | Lee Tien-Li | Chief Executive Officer | P Open-market purchase | 3,500 | $9.94 | +$34.8K |
| 2025-09-16 | Lee Tien-Li | Chief Executive Officer | P Open-market purchase | 6,500 | $9.51 | +$61.8K |
| 2025-09-12 | Lee Tien-Li | Chief Executive Officer | P Open-market purchase | 5,000 | $8.50 | +$42.5K |
| 2025-09-12 | Lee Tien-Li | Chief Executive Officer | P Open-market purchase | 6,000 | $7.82 | +$46.9K |
| 2025-09-12 | Lee Tien-Li | Chief Executive Officer | P Open-market purchase | 9,000 | $7.91 | +$71.2K |
| 2025-09-10 | Sun Nelson | Chief Financial Officer | P Open-market purchase | 6,000 | $8.07 | +$48.4K |
| 2025-08-29 | Lee Tien-Li | Chief Executive Officer | M Option exercise(deriv) | 17,209 | — | +$0 |
| 2025-08-29 | Lee Tien-Li | Chief Executive Officer | M Option exercise | 17,209 | $4.24 | +$73.0K |
| 2025-06-13 | Graf Susan E | Director | A Grant / award(deriv) | 30,508 | — | +$0 |
| 2025-06-13 | Jones Bryan | Chief Operating Officer | A Grant / award(deriv) | 122,033 | — | +$0 |
| 2025-06-13 | Sun Nelson | Chief Financial Officer | A Grant / award(deriv) | 209,826 | — | +$0 |
| 2025-06-13 | Tong Victor Edward Jr | Director | A Grant / award(deriv) | 61,017 | — | +$0 |
| 2025-06-13 | Baynes Roy D. | Director | A Grant / award(deriv) | 30,508 | — | +$0 |
| 2025-06-13 | Jaiman Manasi | Chief Medical Officer | A Grant / award(deriv) | 126,999 | — | +$0 |
| 2025-06-13 | Chi Jeffrey | Director | A Grant / award(deriv) | 61,017 | — | +$0 |
| 2025-06-13 | Lee Tien-Li | Chief Executive Officer | A Grant / award(deriv) | 549,534 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.87 | — | — |
| 2026-05-07 | -0.91 | -0.99 | -8.94% |
| 2026-03-23 | -0.83 | -0.81 | +2.11% |
| 2025-11-13 | -0.82 | -0.75 | +8.09% |
| 2025-08-13 | -0.60 | -0.66 | -9.39% |
| 2025-05-14 | -0.61 | -0.71 | -16.39% |
| 2025-03-31 | -0.20 | -2.18 | -990.00% |